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Abstract 
Dileaver, Steven C., Meenatehieundanan Hariharan, Robin K. Davidson: Pheneleine 
Produces Subsensitivity to Nicotine. Prog. Neuro-Peychopharmacol. & Biol. Peychiat. 
1993, 17(5): 847-860. 
1. The authors attempted to detect a possible effect of treatment with phenelzine 
on a physiological response to nicotine in the rat. 
2. Positive findings in an animal model suggest the feasibility of more 
complicated experiments in animals and the possibility of studies involving 
human subjects. 
3. Treatment of Sprague Dawley rate (n = 10) with phenelzine sulfate (15.0 mg/kg 
ip) every 48 hours for 14 days was associated with a 73.3% decrease in the 
hypothermic response to nicotine. 
4. Treatment with phenelzine did not enhance the rate of elimination of nicotine. 
5. The authors discuss a possible relationship between changes in nicotinic 
mechanisms and the therapeutic actions of drugs used to treat affective 
illness. 
Kevworde: affectivedieordere,.cholinergic, depression, monoamineoxidaee, monoamine 
oxidaee inhibitors, nicotine, phenelzine, receptors, thermoregulation 
Abbreviations: high pressure liquid chromatography (HPLC); intra-peritoneal (ip); 
standard error of the mean (SE&l); ultraviolet (W) 
Introduction 
There is great deal of interest in the relationship between smoking and depression 
(Breelau et al., 1991; Churchill et al., 1989; Covey et. al., 1990; Dileaver et al., 
1990; Glaeeman et al., 1988, 1990). Subjects participating in the National Institute 
of Mental Health sponsored Epidemiologic Catchment Area (RCA) Study who had a history 
of major depression were significantly more likely to have had a history of regularly 
smoking than those individuals with and without another psychiatric disorder. Data 
from this study also indicated that individuals who were depressed were lees 
successful in their efforts to stop smoking than non-affectively ill subjects. 
Breelau and Kilby (1991) recently reported that the probability of participants in 
the study who smoked would have onset of their first episode of major depression 
during a 14 month follow-up interval was much higher than expected by chance. These 
data have created interest in the interaction of drugs used to treat depression with 
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nicotinic cholinergic mechanisms. 
Measurement of the thermic response to nicotine before, in the course of, and 
following chronic treatment is used to screen agents for possible effects on a 
nicotinic mechanism. We used this strategytotestthe hypothesis that treatment with 
phenelsine has nicotinic effects. This drug is a non-specific and irreversible 
inhibitor of monoamine oxidase. Agents with this property are effective 
antidepressants (Liebowite et al., 1984; Paykel, 1989). The monoamine oxidase 
inhibitors, in contrast to the tricyclic antidepressants, do not bind to muscarinic 
(Goldman and Ericson, 1983; Snyder and Yamamura, 1977; Tollefson et al., 1982) or 
nicotinic acetylcholine receptors (Schofield et al., 1981; Shaker et al., 1981). 
These findings have kindled interest in the interaction between drugs used to treat 
affective illness and nicotinic cholinergic mechanisms. 
The data presented indicate that treatment with phenelzine blunts sensitivity 
nicotine. 
uteriale and Methods 
Change in core body temperature in response to the ip injection of 1.0 mg/kg of 
nicotine (base) before and following 7 and 14 days of treatment with phenelzine 
sulfate was measured in Experiment 1. This procedure has proved useful and reliable 
in screening the effects of drugs (Dilsaver and Davidson, 1987 a,b: Dilsaver and 
Hariharan, 1989 a,b; Dilsaver and Hariharan, 1988; Dilsaver and Majchrsak, 1990; 
Dilsaver et al., 1987, 1988, 1989; Majchreak and Dilsaver 1990), drug withdrawal 
(Dilsaver and Majchrsak, 1987), chronic stress (Dilsaver 1988c; Dilsaver et al., 
1986, 1990; Peck et al., 1991) and treatment with bright light (Dilsaver 1988a, 
1990a; Dilsaver and Majchrzak, 1988; Cverstreet et al., 1990 a,b) on muscarinic and 
nicotinic cholinergic mechanisms (Dilsaver and Alessi, 1988 for a review of the 
method). 
The rats used in Experiment 1 continued to receive the same dose of phenelzine 
sulfate every 48 hours for an additional week. Experiment #2 involved the measurement 
of the plasma concentrations of nicotine and cotinine in these animals 30 minutes 
after the ip injection of 1.0 mg/kg of nicotine on day 21 of the study. Nicotine and 
cotinine levels were also measured under identical conditions in a saline treated 
control group. 
Ten (10) adult male Sprague Dawley rats were treated with phenelsine. Their mean 
mass (2 SEX) was 265.8 + 8.5 g at the start of the study. The mean mass of the 8 
saline control animals used in Experiment 2 was 267.5 f. 2.5 g. The animals were 
purchased from Harlan Laboratories (Indianapolis, IN). Care was provided by the 
University of Michigan Laboratory Animal Medicine. 
Pharmaceuticals 
Phenelsine sulfate, nicotine (base) and cotinine were purchased from Sigma 
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Chemical Company (St. Louis, MO, U.S.A). All references to concentrations or doses 
of nicotine and phenelzine refer to the baee and salt forms reepectively. 
ucotine Challenaes 
All challenges with nicotine started at 12:00 pm. Core temperature was meaeured 
immediately before the ip injection of 1.0 mg/kg of nicotine and at 10 minute 
intervals thereafter for 120 minutee. Challenges 2 and 3 occurred on the 7th and 15th 
days of treatment with phenelzine, respectively. 
The Administration of Pheneleine 
Phenelzine wae given by ip injection at 4:00 pm every 40 hours. The dose of 
pheneleine was 15 mg/kg through the entire period of treatment. The second challenge 
with nicotine followed the injectiona of phenelzine Days 2, 4, and 6 of the 
experiment. The injection of nicotine followed the dose of phenelzine given on Day 
6 by 20 hours. The third challenge with nicotine followed additional injections of 
phenelzine on Days 8, 10, 12 and 14 of the experiment. Nicotine was injected 20 hours 
following the dose of phenelzine given on the 14th day of the study. 
Exnerimental Procedure 
Core temperature was measured using biotelemetry. The method is described below. 
The first measurement of temperature is referred to ae the animal's "baseline." This 
ia also referred to as the core temperature at time (t) .= 0. Baseline core 
temperature was measured prior to touching the animal. This is noteworthy as merely 
handling the rat rapidly produces hyperthermia (Dilsaver and Wajchrzak, 1990; 
Dilsaver et al., 1992). 
Temperature at each of the 12 time points following t = 0 was transformed into a 
unit of thermic response by subtracting core temperature at t = 0. Thus, a negative 
number is obtained if core temperature decreases. The average of theee 12 
measurements is the mean thermic responee of an individual rat. Significance of 
change in the thermic response of individual animals to nicotine wa8 determined by 
pairing the thermic response of that animal at each of the 12 time points before and 
after 7 and 14 days of treatment. The mean thermic response of each animal was then 
ueed to determine whether the change in thermic response of the sample was 
significant. 
mrfment 2 
The effect of treatment with phenelzine on the rate of elimination of nicotine was 
measured by injecting 1.0 mg/kg of nicotine into the phenelzine (n = 10) and saline 
(n = 8) treated rats. The experimental and control groups received ip injections of 
15.0 mg/kg (1.0 ml/kg) of phenelzine and normal saline (1 ml/kg), respectively, on 
Daye 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 of the study. 
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Nicotine was injected the morning of the Plst day of the study. Blood was drawn by 
cardiac puncture and placed into heparinizedtubes 30 minutes following the injection 
of nicotine. Plasma was then frozen until the concentration of nicotine and cotinine 
were measured using an HPLC assay with a W detector (Hariharan et al., 1988). 
pfeasurement of Core Temoerature 
Core temperature was measured using the Model VM Mini-&litter (Mini-Mitter Corp., 
Sun River, OR). This instrument consist8 of a thermosensor and radio-transmitter 
which emits AM wavea at a rate directly proportional to temperature. Each Mini-Mitter 
is encased in a waterproof substance (Kerr Sticky WaxR) and is capable of reliable 
operation for more than four months at the normal core temperature of the rat. 
The Mini-Hitter is calibrated each time the casing ia broken. The procedure used 
to calibrate the Mini-Mitter requires measurement of the rate of emission of AN waves 
at three or more temperatures in a temperature controlled water bath (Precision 
Inetruments, 50). These data are used to calculate a linear regression equation. The 
equation is then transformed so that "y" (the dependent variable) is temperature and 
"x" (the independent variable) is the time required to emit a fixed number of AM 
waves. The Mini-Mitter is then implanted into the peritoneal cavity using ether as 
a general anesthetic or the combination of ketamine and a local anesthetic 
(xylazine). The animals are allowed at least 5 days to recover from the implantation 
procedure. 
The Mini-Mitter yields reliable and valid results when used in 
psychopharmacological studies in which the magnitude of effect is of the order 
relevant to this report (Dilsaver et al., 1990). 
Table 1 highlights the time course of the eventa. 
Table 1 







The telemetric thermosensors (Mini-Mitters) are calibrated. 
The thermosensors are implanted into the peritoneal cavity. 
The animals are allowed 5 or more days to recover from the implantation 
procedure. 
Day 1 of the Study 
The animals are challenged with 1.0 mg/kg of nicotine (base) by ip injection at 
12:oo pm. This challenge provides the pretreatment response of each rat to 
nicotine. 
Days 2, 4 and 6 
The experimental and control groups receive 15.0 mg/kg (volume = 1 ml/kg). of 
phenelzine sulfate and 1.0 ml/kg saline, respectively by ip injection at 4:00 pm. 
Day 7 
The animals in the experimental group are challenged with nicotine at 12:OO pm 
on Day 7. The fourth dose of phenelzine or saline is given about 4 hours 






D&y8 8, 10, 12 8nd 14 
Dose6 of phenelsine sulfate or saline are administered. 
Day 15 
The animals are challenged with nicotine for the third time. 
Day 16, 18, and 20 
Doses of pheneleine sulfate or saline are administered. 
Day 21 
Animals in both the experimental and control groups receive an ip injection of 
1.0 mg of nicotine (base). Blood is collected by cardiac puncture 30 minutes 
later and injected into heparinised tubes. Aliguots of plasma are then frozen 
until an HPLC assay with W detection is used to measure the concentrations of 
nicotine a n d c 0 tinine. 
Aaeav of Nicotine 
Plasma levels of nicotine and c&tinine were measured using an HPLC assay coupled 
to W detector. 2-phenylimidaeole (Alrich) was used as an internal standard. The 
mobile phase consisted of 30 m&l citrate buffer, 7% acetonitrile and 2mM sodium 
hepataneeulfonate at a PI-I of 5.0. A C-18 column (Shandon, State College, PA) with a 
length of 150 mm and diameter of 2 mm was used. Evaporation of the organic phase was 
quickened by a flow of nitrogen gas. The residue was then reconstituted with 5 
microliters of the mobile phase. Twenty microliters was then injected into the 
column. The sensitivity of the assay is 1 and 2 ng/ml for nicotine and cotinine, 
respectively. The assay yields linear results from 0 to 600 ng/ml for both 
analysates. All the reagents in the assay are BPLC grade (Hariharan, et al., 1988). 
Statistical Analvsis 
All data in Experiment 1 were subject to analysis using Student's paired t-teet. 
Data in Experiment 2 were analyzed using Student's two sample t-test. All measures 
of variance in the text refer to the SEM. 
Exneriment 1 
Table 2 summarizes the results of this experiment. Nine of the 10 rats exhibited 
blunting of their thermic response to nicotine at p < 0.005 on Day 15. Thus, the 
effect of treatment with the monoamine oxidase inhibitor was not restricted to a few 
animals. 
The mean thermic response of the sample prior to treatment with phenelzine was - 
1.5 + 0.2'C. The mean response was -1.2 + 0.2OC after 7 days of treatment (i.e., 
three doses of phenelzine sulfate). The mean thermic response then decreased to -0.4 
+ O.l'C. (df = 9, t * 3.93, p < 0.0035) following 14 days of treatment (i.e., after 
7 doses of phenelzine sulfate). The raw data are presented in Table 2. Figure 1 
preeents the results of the study. 
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Tab10 2 
S-ry of Tha Ro8ults of Bxporinnt 2 
Promentation of Data 6ntoring into th* Analysis for Experiment 1 
Ratt Mean Core Temperature Response to Nicotine Response to Nicotine after 





















-1.5 + 0.2% -0.4 + O.l%! 
Nine (9) of the 10 rate exhibited significant blunting of the thermic responee to 
nicotine following 14 days of treatment. The exception was rat 3. All numbers 




Fig 1. Mean + SEX thermic response of 10 Sprague Dawley rate to 1.0 mg/kg of nicotine 
(base) before and after a 14 day course of treatment with 15.0 mg/kg phenelzine 
sulfate by ip injection every 48 hours. The change ix significant at p < 0.0035. 
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Nicotine levels in the experimental and control groups were 447 + 27 &ml and 394 
+ 9.0 ng/ml. (df = 16, t = 1.15, p > O-2), respectively. The corresponding levels of 
cotinfne were 230 + 21 nq/ml and 289 2 40 ngfml (df = 16, t = 1.47, p > O.lO), 
respectively. Neither difference was significant. 
Table 3 summarizes the reeulta of the experiment. 
Tsble 3 
Differences in nicotine l d Cotinine Levels in Phenelsino and Saline Treated Rets. 




(1 mg/kg ip) 







48 hours for 21 
days (10 doses) 
447 + 27 ng/nl 
Treatment with 
saline every 48 
hours for 21 days 
(10 doses) 
Absolute value of 
% Difference in 
concentration of 
nicotine (pheneleine 
relative to saline group) 
394 + 9.0 ng/ml 289 + 40 q/ml 
11.9% (ns) 25.7% (ns) 
230 + 21 ng/ml 
The rate of elimination of nicotine did not differ between groups. The percent (%) 
different% = absolute value of [(level of nicotine or cotinine in the pheneleine 
group) - (the level of nicotine or cotinfne in the saline group) divided by the 
levels of nicotine or cotfnine in the phenelzine group )] (100). 
Treatment with phenelzine pxoduced time-dependent subsensitivity to the thermic 
effect of nicotine. Thermfc responsiveness decreased by 20 and 73% following 7 and 
14 days of treatment, respectively. This strongly suggeeta that an acute effect of 
the monoamine oxides% inhibitor does not account for the findings. Experiment 2 
indicates that the animals receivingphenelsine and saline every 48 hours for 21days 
had similar plasma nicotine and cotinine levels 30 minutes after the ip injection of 
1.0 mg/kg of nicotine (base). This suggests that decreased responsiveness to nicotine 
is not due to an increase in its rate of elimination. 
The injection of nicotine at a dose of 1.0 mg/kg ip at 7 day intervals does not 
produce a carryover effect (Dilaaver et al, 1988). It is therefore probable that 
decreased sensitivity to nicotine is due to a phannacodynamic effect of treatment 
with phenelzine. 
Cholin6?raic Prooerties of Druas Used to Treat Affective Disorders 
Jaffe and Sharpless (1968) and Friedman et al. (1969) demonstrated that chronic 
treatment with an antimuecarinic agent produces supersensitivity to a muscarfnic 
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receptor agoniet in an animal model. Muacarinic receptor antagonist6 were 
aubaeguently demonstrated to produce upregulation of muacarinic receptor6 (Dileaver 
1988b; 8hifrin and Klein, 1980; Simian and Klein, 1979; Taylor et al., 1979; Yamada 
et al., 1983). 
The affinities of peripheral and central muacarinic receptor6 for many 
pharmacological treatment6 for depression have been measured (Blackwell et al., 
1978; Goldman and Erickson, 1983; Rahaviet al., 1980 Richeleon and Dinninetz-Romero, 
1977; Snyder and Yamamura, 19771 Seabdi at al., 1972; Tollefaon et al., 1982). The 
tricyclic antidepressant6 specifically bind to these receptors. Chronic treatment 
with theae drugs produces compensatory biochemical and physiological changes in both 
the rat and human subjects (Dilaaver 1989; Dilaaver and Greden, 1983 and 1984; 
Dilaaver and Davidson, 1988; Dileaver et al., 1983 a,b, 1987; Nomura et al., 1982 
a,b). These change6 constitute chemically induced denervation supersensitivity. It 
is manifested by enhanced reaponaiveneaa to acetylcholine and muacarinic receptor 
agonists. 
Phenelxine is devoid of affinity for the muacarinic receptors (Snyder and Yamamura, 
1977). The antimuacarinic-like aide-effect6 produced by thia drug are likely due to 
ita actions on noradrenergic systems (Dileaver 1986 a,b,c; Dileaver and Coffman, 
1989). Iaoproterenol ia an example of a drug devoid of direct 
effecta on muacarinic receptor6 but which can appear to have adrenergic properties. 
Treatment with this beta-blocker increases the deneity of muacarinic receptor6 and 
the acetylcholine-mediated activation of ornithine carboxylaae in the myocardium of 
the rat (Nomura et al, 1982b) by virtue of its interaction with adrenergic neurons. 
Somatic Treatments Bluntina the Thermic Reawnae to Nicotine 
The nicotinic properties of somatic treatments for depression have received very 
little attention. All of the articles included in the MIDLINE database from 1986 to 
January 1992 are cited in this report. Fluoxetine (Dilaaver and Davidson, 1987a), 
deaipramine (Dilaaver et al., 1989) and bright artificial light (Dilaaver 1988a, 
1990a) also produce aubaenaitivity to nicotine in the rat. In contrast, lithium 
(Dileaver and Hariharan, 198933) and amitriptyline (Dilaaver et al., 1988) enhance the 
rat'6 thermic response to nicotine (see Dilsaver and Hariharan,'l989a for a review). 
Theae seemingly incompatible findings can be reconciled. 
The obeervation that various treatment6 for affective illness affect the function 
of nicotinic mechaniama ia compatible with the aminergic theories of ita etiology. 
The nicotinic effects of somatic treatments for the disorders of mood may either be 
causally or indirectly related to events critical to their mechanism of action. 
Nicotine promotes the release of norepinephrine in the hypothalamus (Westfall, 1973) 
and of dopamine within the nigroatriatal and mesolimbic systems (Anderson et al., 
1981). Treatments which mobilize nicotinic mechanisms might secondarily activate 
defective aminergic ayatema. A treatment which enhance6 the activity of sminergic 
mechanisms might induce compensatory eubeensitisation of those nicotinic mechanisms 
with which it interacts in order to preserve homeoatasia. 
Relationshin between Dose of Nicotine and Effect 
The study reported here employed a single dose of nicotine in a repeated measures 
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design. Nicotine rapidly produces tolerance. The use of independent multiple 
samples is more conducive to studying the effects of multiple doses on an endpoint. 
The measurement of the relationship of dose of nicotine to thermic change before and 
after treatment with phenelzine and other agents of interest would be a logical step 
in an effort to demonstrate that these treatments alter sensitivity to nicotine. 
Temperature is an ideal endpoint for this type of study. It is easily measured and 
is contaminated by minimal variance. The available data suggest that phenelzine, 
fluoxetine, bright light, and desipramine will produce a right shift in the dose- 
effect curve (indicating that a higher dose of nicotine is required to produce a 
given hypothermic response to nicotine). Amitriptyline and lithium, should produce 
a left-shift in the curve. These points are illustrated in Fig. 2. 
Dose of 
Nicotine 
Fig. 2 Effects of chronic treatments with amitriptyline and phenalzine. The Chronic 
administration of all six somatic treatments for the affective disorders 
(amitriptyline, desipramine, fluoxetine, lithium, bright light and phenelzine) 
studied to date dramatically alter the thermic response to nicotine. A single dose 
of nicotine was used in this and all previously published reports on this topic. 
Studies designed to detect a possible relationship between dose of nicotine and 
thermic response (dose-response studies) have yet to be conducted. Figure 2 
illustrates the hypothetical results of a study of this type. It indicates that 
chronictreatmentwith amitriptyline and phenelzine increase and decrease by the left 
ehift of the dose-response curve for the group treated with amitriptyline and the 
right shift of the dose-response curve of the group treated with phenelzine, relative 
to the group of receiving no treatment. 
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Nicotinic effects of phenelzine are not likely to be related to its mechanism of 
action if depressed patients in whom it is efficacious do not exhibit altered 
responsiveness to nicotine. Studies indicating a time-dependent change (such as that 
reported here) could prove quite important. 
The effects of acute and chronic treatment with phenelzine and other drugs used to 
treat disorders of mood on the responsiveness of human subjects to nicotine can be 
measured. The effect of intravenous doses of nicotine (Benowits and Jacob, 1990; 
Newhouse et al., 1988) on subjective state, neuroendocrine parameters and body 
temperature can be measured before and in the course of treatment. Studies of this 
type are necessary in order to determine whether the finding reported here may have 
relevance to the mechanism of action of phenelsine. 
&imitations of the Use of a Phvsioloaical Endwint 
Documentation that a given type of experimental intervention (e.g. drug treatment) 
consistently produces changes in a series of physiological endpoints is an excellent 
means of isolating a regularity in nature. Isolation of these regularities would 
hsve once been sufficient data to exercise influence over the way most scientists 
think. However, the history of science has proceeded from the study of events at the 
organismal to cellular and now molecular levels. 
There is a floating concept in the scientific community of Kant's "noumenon" (Kant, 
1781). Neumenon refers "the thing itself." It is reality. Kant emphasized that man 
merely grasps appearances of reality via the all too easily deceived senses. He 
labeled that which is perceived "phenomenon". The ideas of noumenon and phenomenon 
in the sciences are mutable. The isolation of regularities is of the very essence 
of the scientific process. However, the isolation of regularity in an intact animal 
is now merely phenomenon (Dilsaver 1990b). The observations reported here draw 
attention to underlying events which were identified by measuring a physiological 
endpoint. Basic biochemical and electrophysiological studies deeigned to 
characterize the interaction between muscarinic and nicotinic cholinergic mechanisms 






Treatment of the Sprague-Oawley rats with pheneleine sulfate, a non-selective 
monoamine oxidase inhibitor useful in the treatment of depression, resulted in 
subsensitivity to the hypothermic effect of nicotine. 
The effect of treatment was robust. Nine (9) of the 10 rats exhibited 
significant decreases in their hypothermic responses to nicotine after 14 days 
of treatment. The sample exhibited a 73.3% reduction in its hypothermic 
response. 
Treatment with pheneleine did not alter the pharmacokfnetics of nicotine. 
Fluoxetine, desipramine and bright artificial light all reduce the thermic 
response to nicotine. Desipramine retards the metabolism of nicotine yet 
affects decreased sensitivity to its hypothermic effect.. 
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5. Amitriptyline and lithium enhance the thennic response to nicotine. 
6. The authors suggest that at least some somatic treatments for affective 
illness may either directly or indirectly alter the function of nicotinic 
systems. The activation of these systems may enhance the function of 
aminergic mechanisms. Alternatively, the activation of aminergic mechanisms 
may produce compensatory subsensitivity of nicotinic systems. 
Thie work was supported by WHOO553-02 and the University of Michigan, Department 
of Psychiatry. 
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